Loading...
Home2020-12-10T09:29:37+10:00

LTR Medical is an Australian medical device distribution company committed to clinical excellence in the products we supply and the customer service we deliver.

Our vision is to improve patient care and simplify treatment for health-care providers. We source and supply safe and effective medical and surgical devices for hospitals, medical practices and home carers.

LTR Medical products are selected based on an exceptionally high standard of clinical efficiency and excellence in safety, design and delivery. Our product range is sourced from trusted, high quality medical device developers and manufacturers committed to clinical excellence and patient safety, distributed by LTR Medical throughout Australia and New Zealand.

Our Products

SAFIRA™

Discover more

CA-500

Discover more

Accufuser

Discover more

Accumate 1200

Discover more

MICROi Blade

Discover more

Springfusor and FCT

Discover more

V-Set

Discover more

Amnicot

Discover more

Nasal Spray

Discover more

O’Neil Urinary Catheter

Discover more

Eldor Catheter Kit

Discover more

Med XL

Discover more

Oxyfriend

Discover more

CIMPAX Wound Infiltration Kit

Discover more

News

CitraFlow™ 4%, 30% and 46.7% Prefilled Syringes

LTR Medical is pleased to announce that CitraFlow™ Prefilled Syringes have gained TGA approval. CitraFlow™ 4%, 30% and 46.7% prefilled syringes are a proven alternative to heparin for flushing and locking catheters/ports on patients. Sodium citrate avoids the risks associated with systemic heparinisation and is safe for use in patients with suspected or confirmed Heparin Induced Thrombocytopenia. Clinical studies have shown that the use of ananticoagulant Sodium Citrate solution to lock central venous catheters has significant advantages compared to existing standards of care. CitraFlow™ is highly effective in maintaining catheter patency, works as an anticoagulant and decreases the incidence of infection. CitraFlow™ is designed for use in a sterile field. For more information, visit our product page MedXL - LTR Medical or call us on 1800 319 419

SAFIRA™ SAFer Injeciton for Regional Anaesthesia

LTR Medical is proud to announce that with TGA approval we will move to the next stage in launching the SAFIRA™ - SAFer Injection for Regional Anaesthesia in the Australian and New Zealand markets. Manufactured by Medovate, the SAFIRA™ gives Anaesthetists control over regional anaesthesia blocks by making it a single operator procedure.  With an engineered safety solution to control injection pressure threshold, it reduces the change of nerve injury. LTR Medical CEO Lee Rodne commented: “The team at LTR Medical are excited to introduce the SAFIRA® to the Australian and New Zealand Markets. This groundbreaking new technology gives Anaesthetists greater control when placing nerve blocks and reduces the chance of nerve damage, improving patient outcomes.” For further information, visit our product page or call us on 1800 319 419.

Introducing the CA-500 Ambulatory Syringe Pump

LTR Medical is excited to launch the CA-500 Ambulatory Syringe Pump in the Australian and New Zealand markets. The CA-500 is a portable, intuitive syringe pump ideal for delivery of medications and fluids in small volume and low rate. With a comprehensive range of features, the pump is suitable for infusion therapy across a wide variety of applications in inpatient, outpatient and home care environments. For further information, please visit our product page – CA-500 Ambulatory Syringe Pump – or call us on 1800 319 419. #infusion #HITH #palliativecare #patientsafety

LTR Medical to distribute the SAFIRA™ in Australia and New Zealand

LTR Medical has concluded a distribution agreement with Medovate, the medical device development company which will provide exclusivity for SAFIRA® (SAFer Injection for Regional Anaesthesia) in Australia and New Zealand. Developed in collaboration with anaesthetists in the UK National Health Service (NHS), SAFIRA® is set to help revolutionise standard regional anaesthesia clinical practice. With the use of regional anaesthesia continuing to grow significantly in Australia and New Zealand, SAFIRA® has the potential to make a significant impact. Amid the current COVID-19 pandemic, recent publications have recommended regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. This is because regional anaesthesia preserves respiratory function and avoids aerosolisation and the potential for transmission of COVID-19 compared to general anaesthesia. Already launched across the United States, this distribution agreement to bring SAFIRA® to market in Australia and New Zealand marks a significant further step in making this [...]

Call us Now

Call us for more information on our products on 1800 319 419.

Contact us today!
Go to Top